Allogene Therapeutics (ALLO) Other Gross PP&E Adjustments: 2019-2025
Historic Other Gross PP&E Adjustments for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $104.5 million.
- Allogene Therapeutics' Other Gross PP&E Adjustments fell 23.16% to $104.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.4 million, marking a year-over-year decrease of 7.09%. This contributed to the annual value of $81.5 million for FY2024, which is 32.53% up from last year.
- Latest data reveals that Allogene Therapeutics reported Other Gross PP&E Adjustments of $104.5 million as of Q3 2025, which was up 0.60% from $103.9 million recorded in Q2 2025.
- Over the past 5 years, Allogene Therapeutics' Other Gross PP&E Adjustments peaked at $140.9 million during Q2 2024, and registered a low of $40.4 million during Q4 2022.
- Moreover, its 3-year median value for Other Gross PP&E Adjustments was $86.1 million (2024), whereas its average is $93.6 million.
- Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first slumped by 45.13% in 2022, then soared by 101.04% in 2024.
- Over the past 5 years, Allogene Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at $73.6 million in 2021, then plummeted by 45.13% to $40.4 million in 2022, then spiked by 52.25% to $61.5 million in 2023, then soared by 32.53% to $81.5 million in 2024, then dropped by 23.16% to $104.5 million in 2025.
- Its last three reported values are $104.5 million in Q3 2025, $103.9 million for Q2 2025, and $104.6 million during Q1 2025.